Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline

Strengthening of strategic option license agreement to cover additional novel ADC targets

Copenhagen, Denmark, May 30th, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, announced the expansion of its current collaboration with Duality Biologics (“Duality”), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate therapeutics.

Read more…